吉林英联尚德科技开发

Jilin Yinglian Shangde Technology Development is a Chinese biopharmaceutical company focused on the research and development of innovative small molecule therapeutics for central nervous system (CNS) disorders, particularly epilepsy. The company's lead candidate is Phenzolzine (also known as Q808 or Benzoxazine), a novel Class 1.1 chemical drug currently in Phase 1 clinical trials in China. Phenzolzine acts as a broad-spectrum anticonvulsant by modulating the GABAergic system, specifically increasing GABA levels in the hippocampus to prevent over-excitation of neurons. Jilin Yinglian Shangde collaborates with academic institutions, such as Zhejiang Chinese Medical University and Yanbian University, to advance its pipeline of neuroprotective and antiepileptic therapies.